focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
All indicators are pointing towards very positive sales so far. I'm expecting this to far exceed expectations.
Forget the negative reviews as they themselves acknowledge this won't work for everyone (not to mention forces looking to de-value the product)
Yes, all SH were expecting a higher bump to the SP on the FDA news, but this will no doubt come in time. Next week's seminars may or may not reveal some initial figures, but I imagine the SP will rise following those meetings regardless.
The year so far has been unbelievably positive in terms of milestones achieved, so lets hope the SP does reflect this in due course. Patience again is the order of the day.
15% up from the low in steady fashion is pleasing. We are getting closer to FDA-day - in the next 3 weeks we will certainly have an update one way or another. Given what is online about FDA decision timeframes, I won't be surprised if there is a further delay, but crossing fingers that isn't the case (and the update is positive!)
JB back on with Proactive
https://www.youtube.com/watch?v=i0lbaZqEWaE
Dr Hilary Jones on UK morning TV did a good job in the 2 minute section at the beginning on the 9am slot. He covered most of the main areas including the requirement/need, ease of use, clinical trials data, rapid onset/spontaneity, partner involvement, no adverse side effects, OTC/availability, first major breakthrough since the 90s....
Rome wasn't built in a day. With respect, you cant expect a new medical product to be available in every Pharmacy in a whole country/continent overnight. There seems to be a clear approach with how they are launching this, however, I do understand your POV when it comes to the wording used on different sites. I would say you won't have to wait much longer. Good things come to those who wait... to coin another phrase in this post!
On Futura website:
Eroxon Stimgel will be available in European countries soon. Eroxon Stimgel can already be found online on the following buying platforms:
www.shop-apotheke.com
www.shop-pharmacie.fr
www.farmaline.be
Personally, I am amazed that the SP is at the level it is, given the product has been soft-launched and the other recent events. I understand there is some frustration that it's not a crash, bang, wallop fanfare launch, but this is clearly by choice.
Time after time, it has been said that there is 'sensitivity' around what can be said. Think back several years and many newspapers here in the UK and online articles appeared - and this is more than likely going to be the case once it is released in the UK market (in the next few weeks you'd think given the updated info on the Eroxon website and other signs)
The guide price given by Trinity and others is close to where I feel this should be sitting currently. Once the FDA news lands, expect this to go way higher than many probably expect. It all seems like this is the tipping point, especially as there has been limited marketing etc to this point. FDA news (expecting this to be positive of course!), UK launch, further launches in Asia and other markets, increased media attention etc are all around the corner. You have to say the current SP looks like a steal.
My estimates are 200-350 by EOY. Beyond that will ultimately depend on competition, buyouts, user reviews and numerous other factors.
Next couple of weeks could be very interesting...
Just to clarify this - the aim the FDA give for approval of a de-novo application is 150 days. Say they came back requesting further information around day 120, the 'clock' stops there, and starts again from day 120 when the question's response has been submitted. It does not 'reset' at day zero.
Therefore, JB gave an indication that once the questions had been answered by end of March (which they have done) the clock restarts, with 30 days left on the clock, hence estimation of "by end of Q2", but given the October RNS stating they were about to submit, the date is closer to beginning of Q2 (April) rather than the end (June)
PDW - wrt to the 'clock' JB said recently that the FDA have a 150 day process, and the clock stops on this if they ask for additional data, then starts again once FM submit the answers which they will do before eo March (if not already as I suspect). We were very close to the 150 day mark already (which is where the initial Q123 timeframe came from following submission) - so I am very confident the final decision will be very early in Q223 (end of April latest IMO).
I think some of the comments directed towards the BOD and Futura are misplaced. They are under obvious restrictions on what information they can release, as a lot of the commercial launch plans sits with Cooper and others. They have said it will be a 'soft' launch initially, followed by more marketing and advertising in the coming weeks.
Nothing they have said in recent months on various platforms, has not been true IMO. I do however think there was some knowledge amongst certain SH of the FDA decision which impacted the SP ahead of the RNS, and following drop in price - I've taken this drop in SP as an opportunity to buy, as nothing I have seen or heard makes me any less bullish - a few weeks delay to FDA decision (which was always likely given the nature of MED3000) is not cause for such alarm - I think some big fish are playing the game very well.
Lets hope they have now, or are close to answering the questions the FDA asked and the clock starts again.
It is clear there are some LTH who just want this to go 5x overnight, which it may well do, but patience seems to be waiting, hence the more personal slanging going on in this chat.
GLA all. I for one am not concerned at all and think we have many exciting months ahead on 2023.
I would say that a potential 3 month delay is hardly the worst news, and I expect FDA approval is no walk in the park, and likely to have additional questions asked. The rest of the RNS was extremely positive with the EU marketing ad promo campaigns imminent. 10%+ discount for 12 weeks more patience.... go on then!
Completely agree. Nothing I am seeing contradicts the RNS messaging, and feel things are on track. Can certainly understand the feelings of impatience, but that is natural if you have been holding long term.
Agree. I'm sure FM chose Cooper wisely, and considering they are the biggest independent selfcare organization in Europe, they should know what they're doing! SH will always get a little impatient this close to long awaited events. Potentially a good opportunity here to pick up a little more, I know I have....nfa
https://hcp.eroxon.co.uk/hcpentry/ed-treatments
FDA notification should be any day now. 'Ready to submit' RNS on this was 03/10 - 150 days from that date is 02/03 - if submission took place shortly after the RNS, then it could be any day now...
Eroxon’s novel treatment for ED is already available without prescription in the EU and UK and is expected to receive a similar regulatory status in many other parts of the world. Our commercial partner for this region, Cooper Consumer Health, has already launched the product in Belgium with further launches expected in Europe this year. Eroxon is also available online via Amazon and Apotheke on their European platforms.
I suspected we would range between 50-55 for some time with no further updates since last RNS, but there has been some hefty sells in recent days. We are 2-3 weeks from NDA yay/nay news, with EU 'launch' also very close. Exciting times.